RecruitingPhase 2NCT06454578

Adjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative Resection

Studying Pediatric hepatocellular carcinoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Qilu Hospital of Shandong University
Principal Investigator
Tao Li, Dr
Qilu Hospital of Shandong University
Intervention
Adebrelimab + Apatinib(drug)
Enrollment
30 enrolled
Eligibility
18 years · All sexes
Timeline
2024 – 2027

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06454578 on ClinicalTrials.gov

Other trials for Pediatric hepatocellular carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Pediatric hepatocellular carcinoma →

← Back to all trials